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croenvironment. However, we agree with Arnaud 
et al. that the exact molecular basis of T-cell acti-
vation, especially in the case of psoriasis, needs to 
be addressed in further studies.
Borriello and De Palma address the important 
aspect of clinical decision making. Historically, 
the diagnosis of atopic eczema and the hyper-
IgE syndrome has been based on clinical pheno-
typing and laboratory findings. Patient 2 did not 
fulfill these criteria for the hyper-IgE syndrome.3 
However, as Borriello and De Palma state, both 
diseases are heterogeneous, and the clinical pre-
sentations overlap. With increasing knowledge of 
altered molecular pathways and distinct genetic 
mutations, several disease subgroups may be iden-
tified. Such a process has been observed in the 
field of cancer, in which detailed knowledge of 
the pathogenesis of diseases such as melanoma4 
is the basis for an individualized molecular ther-
apy. Interestingly, no patient with atopic eczema 
in our article was filaggrin-deficient, which could 
indicate a “T-cell-driven” or “antigen-dependent” 
type of atopic eczema. Certainly, the way to pro-
ceed is to identify the precise molecular and ge-
netic alterations of individuals rather than groups 
of patients.
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Coagulopathy of Chronic Liver Disease
To the Editor: In their review article, Tripodi 
and Mannucci (July 14 issue)1 present data that 
suggest a procoagulant imbalance in cirrhosis. 
Resistance to anticoagulation that is mediated by 
thrombomodulin2 and an increased relative risk 
of venous thromboembolism3 indicate that pa-
tients with cirrhosis do not undergo anticoagula-
tion because of their increased prothrombin time. 
Consequently, the rationale to administer fresh-
frozen plasma to correct the prothrombin time 
before invasive procedures is debated.
One of the invasive procedures that is most 
frequently performed in patients with decompen-
sated cirrhosis is diagnostic or large-volume para-
centesis. Even in patients with elevated values for 
the international normalized ratio, bleeding af-
ter paracentesis occurs in a very low percentage 
of patients,4 and there is no evidence that a pro-
longed prothrombin time is associated with a risk 
of bleeding after this procedure.5 These findings 
indicate that a prolonged prothrombin time is 
not associated with a clinically relevant hypoco-
agulable state in patients with cirrhosis. There-
fore, avoiding the administration of fresh-frozen 
plasma before paracentesis in patients with cir-
rhosis should be considered, since the risks and 
costs may exceed the real benefit for the patient.
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To the Editor: Tripodi and Mannucci indicate 
that anticoagulation should be commonly used 
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in patients with cirrhosis who have portal-vein 
thrombosis caused by a procoagulant imbalance. 
However, a prospective study has shown that the 
only independent predictor of portal-vein throm-
bosis in liver cirrhosis is a reduced velocity in por-
tal-vein flow.1 This finding suggests that the most 
critical issue for the treatment of portal-vein throm-
bosis in patients with cirrhosis should be how to 
improve portal-vein flow. In this situation, the ben-
efit of the placement of a transjugular intrahepat-
ic portosystemic shunt (TIPS) is prominent, be-
cause the procedure not only recanalizes the 
thrombosed portal vein by means of endovascular 
manipulation but also increases the portal blood-
flow velocity by creating a portosystemic shunt.2,3 
Until now, data for 243 patients with cirrhosis and 
portal-vein thrombosis who underwent TIPS have 
been reported in 10 case series (unpublished data). 
By contrast, the use of anticoagulation for portal-
vein thrombosis in patients with cirrhosis has been 
reported in only three case series. Notably, antico-
agulation is often used in patients with partial 
portal-vein thrombosis but rarely in those with 
complete portal-vein thrombosis or portal caver-
noma.4 In addition, questions remain about the 
type, dose, and duration of anticoagulation. 
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To the Editor: A procoagulant state is detected 
in liver cirrhosis and may be responsible for an 
enhanced rate of vein thrombosis. Tripodi and 
Mannucci suggest that an imbalance between in-
creased values of factor VIII and reduced natural 
anticoagulants such as protein C may account for 
the procoagulant state. Enhanced circulating lev-
els of von Willebrand factor are suggested to im-
pair factor VIII clearance, but the underlying mech-
anism is not fully clarified. We have previously 
shown that endotoxemia plays a role, since it is 
enhanced in patients with cirrhosis and may re-
lease von Willebrand factor from endothelial cells.1 
Interestingly, endotoxemia may elicit a procoagu-
lant state with an alternative mechanism, since it 
enhances the expression of tissue factor (with en-
suing clotting activation) in monocytes obtained 
from patients with cirrhosis.2 This effect is more 
pronounced in the portal circulation of patients 
with cirrhosis in whom endotoxemia could be a 
trigger for thrombosis.3 The treatment of such 
patients with nonabsorbable antibiotics resulted 
in parallel reduction of endotoxemia, von Wille-
brand factor, and clotting activation,4 which sug-
gests that this approach may lower the procoagu-
lant state in patients with cirrhosis.
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The authors reply: We agree with De Gottardi 
that there is no need for plasma prophylaxis in 
patients with an abnormal prothrombin time who 
undergo paracentesis.1 A rescue strategy (i.e., wait 
and see if bleeding occurs) is more reasonable, al-
though evidence stemming from controlled clin-
ical trials is needed.
Like Qi et al., we had indeed emphasized in 
our review article that reduced flow velocity is one 
of the determinants of portal-vein thrombosis.2 
However, reduced flow velocity, in addition to 
vessel-wall abnormalities and procoagulant im-
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balance (i.e., reduced levels of protein C and in-
creased factor VIII), are also mechanistic factors 
for Virchow’s triad, which leads to an increased 
risk of venous thrombosis. Therefore, we believe 
there is a rationale for using anticoagulation in 
patients with portal-vein thrombosis. Further-
more, TIPS, although effective for the treatment 
of portal-vein thrombosis, is an invasive proce-
dure.3 Therefore, we consider TIPS a second-line 
therapeutic option to be implemented only when 
there are concomitant complications related to 
portal hypertension or when thrombosis expands 
despite anticoagulant therapy. 
As pointed out by Violi et al.,4 the occurrence 
of endotoxemia might play a role in the pertur-
bation of hemostasis in end-stage liver disease 
through alterations of fibrinolysis or the occur-
rence of disseminated intravascular coagulation. 
However, the role that is played by the above con-
ditions cannot be easily ascertained in the clini-
cal context, owing to the lack of relatively simple 
global laboratory tests that truly reflect the con-
ditions operating in vivo. For instance, increased 
levels of prothrombin fragment F1+2 or d-dimer, 
which are regarded by Violi et al.4 as indexes of 
coagulation activation, may instead be the con-
sequence of the decreased clearance of these pep-
tides from the circulation owing to impaired liver 
function rather than to ongoing coagulation acti-
vation. Hence, the association of these abnormali-
ties with bleeding or thrombotic complications in 
end-stage liver disease cannot be easily shown. 
Finally, the question of whether the administra-
tion of nonabsorbable antibiotics truly helps to 
limit the procoagulant imbalance in end-stage liver 
disease, as suggested by Violi et al., should be 
more thoroughly investigated in prospective, ran-
domized clinical trials. However, we maintain that 
antibiotics are less likely than anticoagulants to 
affect the plasma procoagulant imbalance because 
of the reduced levels of protein C and increased 
factor VIII that are distinctive features of chron-
ic liver disease.
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The Avastin Story
To the Editor: Recently, the Food and Drug Ad-
ministration (FDA) held an administrative hear-
ing regarding the proposal to withdraw acceler-
ated approval from Avastin (bevacizumab) for 
metastatic breast cancer. I served as a member of 
the Oncologic Drugs Advisory Committee (ODAC) 
at that meeting. Two recent online Perspective 
articles, by Carpenter et al.1 and D’Agostino,2 ad-
dressed the use of surrogate end points and the 
regulatory and political issues surrounding this 
hearing. But neither article covered a basic, pa-
tient-focused theme that we, the oncologists on 
the panel, considered: that of giving hope — but 
not false hope.
Avastin received accelerated approval from the 
FDA for metastatic breast cancer in 2008 on the 
basis of a study in which patients who were 
treated with Avastin, in combination with pacli-
taxel, had a progression-free survival advantage 
of 5.5 months over paclitaxel alone but no over-
all survival advantage.3 Toxic effects were sub-
stantial, but this interim end point suggested real 
clinical benefit. Unfortunately, in what were sup-
posed to be confirmatory studies enrolling al-
most 2000 women, progression-free survival was 
shorter than in the initial study, and no quality-
of-life or survival advantage could be shown for 
Avastin-containing regimens.
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